Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - docetaxel -

United States - English - NLM (National Library of Medicine)

teva parenteral medicines, inc. - docetaxel anhydrous (unii: 699121phca) (docetaxel anhydrous - unii:699121phca) - docetaxel anhydrous 20 mg in 1 ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - docetaxel - solution for infusion - 20mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - docetaxel - solution for infusion - 20mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - docetaxel - solution for infusion - 20mg/1ml

United States - English - NLM (National Library of Medicine)

actavis pharma, inc. - docetaxel (unii: 15h5577cqd) (docetaxel anhydrous - unii:699121phca) - docetaxel anhydrous 20 mg in 1 ml

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - docetaxel - concentrate for solution for infusion - 20 milligram(s)/millilitre - taxanes; docetaxel

United States - English - NLM (National Library of Medicine)

mylan institutional llc - docetaxel anhydrous (unii: 699121phca) (docetaxel anhydrous - unii:699121phca) - docetaxel injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. docetaxel injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. docetaxel injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. docetaxel injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. docetaxel injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. docetaxel injection in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced ga

United States - English - NLM (National Library of Medicine)

mylan institutional llc - docetaxel anhydrous (unii: 699121phca) (docetaxel anhydrous - unii:699121phca) - docetaxel injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. docetaxel injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. docetaxel injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. docetaxel injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. docetaxel injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. docetaxel injection in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced ga

United States - English - NLM (National Library of Medicine)

mylan institutional llc - docetaxel anhydrous (unii: 699121phca) (docetaxel anhydrous - unii:699121phca) - docetaxel injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. docetaxel injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. docetaxel injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. docetaxel injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. docetaxel injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. docetaxel injection in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced ga